Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,582.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 12,398 shares of the biopharmaceutical company’s stock after acquiring an additional 11,661 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $1,669,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Strs Ohio acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $141,000. CENTRAL TRUST Co boosted its stake in Alnylam Pharmaceuticals by 746.3% during the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $165,000. QS Investors LLC boosted its stake in Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares during the period. 88.59% of the stock is owned by hedge funds and other institutional investors.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $115.92 on Monday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $44.50 and a 1-year high of $147.63. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 48.88%. The firm had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter in the prior year, the firm earned ($1.32) EPS. The firm’s revenue was up 116.6% compared to the same quarter last year. equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.69 earnings per share for the current year.

A number of research firms have commented on ALNY. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 8th. Credit Suisse Group set a $151.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday. FBR & Co began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 price target on the stock. BMO Capital Markets dropped their price target on shares of Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Cowen restated an “outperform” rating and set a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $126.98.

In related news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 73,415 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the transaction, the chief executive officer now directly owns 223,125 shares in the company, valued at $29,207,062.50. The disclosure for this sale can be found here. Insiders have sold 220,409 shares of company stock worth $28,667,017 over the last ninety days. 4.30% of the stock is currently owned by insiders.

WARNING: “Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $1.67 Million Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/12/mitsubishi-ufj-kokusai-asset-management-co-ltd-has-1-67-million-holdings-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.